Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Abstract Background Both serotonergic signalling disruption and systemic inflammation have been associated with the pathogenesis of Alzheimer’s disease (AD). The common denominator linking the two is the catabolism of the essential amino acid, tryptophan. Metabolism via tryptophan hydroxylase result...

Full description

Bibliographic Details
Main Authors: Luke Whiley, Katie E. Chappell, Ellie D’Hondt, Matthew R. Lewis, Beatriz Jiménez, Stuart G. Snowden, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Jonathan R. Swann, Abdul Hye, Simon Lovestone, Cristina Legido-Quigley, Elaine Holmes, on behalf of AddNeuroMed consortium
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Kynurenine
Tryptophan
Serotonin
Metabolic phenotyping
Mass spectrometry
Online Access:https://doi.org/10.1186/s13195-020-00741-z

Similar Items

Similar Items